- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02141438
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (REASSURE)
March 21, 2024 updated by: Bayer
Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation
Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
1474
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Multiple Locations, Argentina
-
-
-
-
-
Multiple Locations, Austria
-
-
-
-
-
Multiple Locations, Belgium
-
-
-
-
-
Multiple Locations, Canada
-
-
-
-
-
Multiple Locations, Colombia
-
-
-
-
-
Multiple Locations, Czechia
-
-
-
-
-
Multiple Locations, Denmark
-
-
-
-
-
Multiple Locations, France
-
-
-
-
-
Multiple Locations, Germany
-
-
-
-
-
Multiple Locations, Greece
-
-
-
-
-
Multiple Locations, Israel
-
-
-
-
-
Multiple Locations, Italy
-
-
-
-
-
Multiple Locations, Luxembourg
-
-
-
-
-
Multiple Locations, Mexico
-
-
-
-
-
Multiple Locations, Netherlands
-
-
-
-
-
Multiple Locations, Portugal
-
-
-
-
-
Multiple Locations, Spain
-
-
-
-
-
Multiple Locations, Sweden
-
-
-
-
-
Multiple Locations, United Kingdom
-
-
-
-
Alaska
-
Anchorage, Alaska, United States
-
-
Arizona
-
Scottsdale, Arizona, United States
-
-
California
-
Daly City, California, United States
-
Long Beach, California, United States
-
Sacramento, California, United States
-
San Diego, California, United States
-
-
Colorado
-
Colorado Springs, Colorado, United States
-
-
Florida
-
Boca Raton, Florida, United States
-
Fort Myers, Florida, United States
-
Jacksonville, Florida, United States
-
Lakewood Ranch, Florida, United States
-
Plantation, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
Decatur, Georgia, United States
-
-
Hawaii
-
Honolulu, Hawaii, United States
-
-
Illinois
-
Evanston, Illinois, United States
-
Warrenville, Illinois, United States
-
-
Kansas
-
Wichita, Kansas, United States
-
-
Kentucky
-
Ashland, Kentucky, United States
-
-
Louisiana
-
New Orleans, Louisiana, United States
-
-
Maryland
-
Baltimore, Maryland, United States
-
Rockville, Maryland, United States
-
Towson, Maryland, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Michigan
-
Troy, Michigan, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
-
Montana
-
Billings, Montana, United States
-
-
Nebraska
-
Omaha, Nebraska, United States
-
-
New Hampshire
-
Lebanon, New Hampshire, United States
-
-
New Jersey
-
Neptune, New Jersey, United States
-
Township, New Jersey, United States
-
-
New York
-
Buffalo, New York, United States
-
East Setauket, New York, United States
-
Lake Success, New York, United States
-
-
North Carolina
-
Winston-Salem, North Carolina, United States
-
-
Ohio
-
Middleburg Heights, Ohio, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
-
Oregon
-
Springfield, Oregon, United States
-
-
Pennsylvania
-
Abington, Pennsylvania, United States
-
-
South Carolina
-
Charleston, South Carolina, United States
-
Myrtle Beach, South Carolina, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Houston, Texas, United States
-
Lubbock, Texas, United States
-
San Antonio, Texas, United States
-
Temple, Texas, United States
-
-
Virginia
-
Charlottesville, Virginia, United States
-
Virginia Beach, Virginia, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with histologically or cytologically confirmed castration resistant adenocarcinoma of the prostate with bone metastases for whom the treatment decision to Radium-223 has been made independent from and before patient enrolment in the study.
Description
Inclusion Criteria:
- Treatment decision to Radium-223 needs to be made independent from and before patient enrollment in the study
- Histologically or cytologically confirmed castration resistant adenocarcinoma of the prostate with bone metastases
- Signed informed consent
Exclusion Criteria:
- Previously treated with Radium-223 for any reason
- Currently treated in clinical trials including other Radium-223 studies
- Planned for the systemic concomitant use of other radiopharmaceuticals for treatment of prostate cancer or for other use
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Radium-223 dichloride (Xofigo, BAY88-8223)
Single-arm cohort observational study with CRPC patients with bone metastasis treated with Radium-223.
|
This is a non-interventional study, the drug is used in its authorized indication from commercial supply.
The decision to treat with Radium-223 will be agreed upon between the physician and the patient independently and prior to providing the patient study information.
Treatment with Radium-223 should follow the approved local product information.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of developing second primary malignancies
Time Frame: From study start to 7 years post last dose of Radium-223
|
From study start to 7 years post last dose of Radium-223
|
|
Incidence of treatment-emergent SAEs
Time Frame: From study start up to 30 days after the last administration of Radium-223
|
From study start up to 30 days after the last administration of Radium-223
|
|
Incidence of drug-related treatment-emergent adverse events
Time Frame: From study start up to 30 days after the last administration of Radium-223
|
From study start up to 30 days after the last administration of Radium-223
|
|
Incidence of drug-related SAEs
Time Frame: From study start to 7 years post last dose of Radium-223
|
From study start to 7 years post last dose of Radium-223
|
|
Bone marrow suppression
Time Frame: From study start to 6 months post last dose of Radium-223
|
Therapeutic/prevention measures/treatment modalities, Gr. 3/4 hematological toxicities (up to 6 months after last administration), platelet or WBC < lower limit of normal during treatment +30 days will be followed to resolution (up to 6 months after last administration), and febrile neutropenia and hemorrhage for patients who start subsequent chemotherapy will be assessed.
|
From study start to 6 months post last dose of Radium-223
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: From study start to 7 years post last dose of Radium-223
|
From study start to 7 years post last dose of Radium-223
|
|
The worst pain score and pain interference score over time as determined by patient responses on the "Brief pain inventory short form" (BPI-SF) questionnaire
Time Frame: From study start to 6 months post last dose of Radium-223
|
From study start to 6 months post last dose of Radium-223
|
|
Incidence of bone fractures
Time Frame: From study start to 7 years post last dose of Radium-223
|
From study start to 7 years post last dose of Radium-223
|
|
The number of bone associated events
Time Frame: From study start to 7 years post last dose of Radium-223
|
e.g. osteoporosis
|
From study start to 7 years post last dose of Radium-223
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Bayer Study Director, Bayer
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 20, 2014
Primary Completion (Estimated)
August 2, 2024
Study Completion (Estimated)
February 28, 2025
Study Registration Dates
First Submitted
May 15, 2014
First Submitted That Met QC Criteria
May 15, 2014
First Posted (Estimated)
May 19, 2014
Study Record Updates
Last Update Posted (Actual)
March 22, 2024
Last Update Submitted That Met QC Criteria
March 21, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16913
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Castration-resistant Prostate Cancer
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
Rohan GarjeJanssen Scientific Affairs, LLCNot yet recruitingCastration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
BAMF HealthRecruitingMetastatic Castration-resistant Prostate CancerUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Clarus TherapeuticsRecruitingProstate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Massachusetts General HospitalBayerCompletedProstate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to BoneUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingMetastatic Castration-resistant Prostate CancerChina
-
Hinova Pharmaceuticals Inc.CompletedMetastatic Castration Resistant Prostate CancerChina
Clinical Trials on Radium-223 dichloride (Xofigo, BAY88-8223)
-
BayerCompletedProstate CancerUnited States
-
BayerCompletedMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
BayerCompletedProstatic NeoplasmsChina, Singapore, Taiwan, Korea, Republic of
-
BayerCompletedBone Metastatic Castration-resistant Prostate CancerGermany, Netherlands, Denmark
-
BayerCompletedProstatic Neoplasms, Castration-ResistantUnited States
-
BayerTerminatedBone Metastases | Metastatic Castration-resistant Prostate CancerChina